Предикторы прогрессирования гипертрофии левого желудочка у больных стабильной стенокардией в сочетании с артериальной гипертензией и оценка кардиопротективного эффекта ивабрадина в ее регрессе
Диссертация
Внедрение в практику. Результаты работы внедрены в практику кардиологического и терапевтического отделений МУЗ МСЧ № 9 им. М. А. Тверье г. Перми, терапевтических отделений № 3,4,7 ГУЗ ПКГВВ. Материалы диссертации используются в преподавании на кафедре внутренних болезней педиатрического и стоматологического факультетов ГОУ ВПО «Пермская государственная медицинская академия им. ак. Е. А. Вагнера… Читать ещё >
Список литературы
- Алмазов В. А. Шляхто В.А., Соколова Л. А. Пограничная артериальная гипертензия. Спб., 1992. С. 23−87.
- Белоусов Ю.Б., Шляхто Е. В. и соавт., Артериальная гипертезия, Т.10, № 4, 2004. С. 44−65.
- Голошапов О.В. и соавт. Разнонаправленное влияние нифедипина и Ь-блокатора пропранолола на вариабельность ритма сердца у больных артериальной гипертонией. Тезисы VII Российского национального конгресса «Человек и лекарство», 2000. С. 32.
- Закирова А.Н., Закирова Н. Э., Клочкова Г. Р., Мусина Ф. С. Ремоделирование миокарда при ишемической болезни сердца. Рациональная фармакотерапия в кардиологии. 2009. Том 5. № 1. С. 4245.
- Кобалава Ж.Д., Котовская Ю. В., Артериальная гипертония: ключи к диагностике и лечению. Москва, 2007. С. 105−142.
- Конради А.О. Ремоделирование сердца и крупных сосудов при гипертонической болезни. Автореферат дис. д-ра мед. наук. Спб., 2003. С. 101−114.
- Лышова О. В. Провоторов В.М. Всероссийский научно-практическийсеминар «Современные возможности холтеровского мониторирования»: Сб. тезисов. СПб., 2000- № 5. С. 13−29.
- Мазур Н.А. Профилактика сердечно-сосудистых осложнений у больных артериальной гипертонией. М: Медпрактика 2003- 13−16.
- Мазур Н. А, Очерки клинической кардиологии. М., МИА, 1999, С. 156 207.
- Мазур, Е.С. Влияние ишемической болезни сердца на суточный ритм артериального давления / Е. С. Мазур, В. В .Мазур, И. М. Омар // Сборник научных трудов «. Организационно-методические и диагностические вопросы медицины «. — Тверь., 2001. С. 33−56.
- Мойбенко А., А.Н. Пархоменко, Я. М. Лутай, В. Е. Досенко, Н. В. Довгань, Вторичная профилактика инфаркта миокарда: новые данные — новые перспективы. Медицинская газета «Здоровье Украины», 2005, 24/1: 12−14.
- Рекомендации специальной комиссии Европейского общества кардиологов: Лечение стабильной стенокардии. // РМЖ.- 1998.- Т. 6.-№ 1 С. 3−28.
- Соболев А.В., Рябыкина Г. В. Мониторирование ЭКГ с анализом вариабельности ритма сердца — М.: ИД «Медпрактика-М», 2005, 183 215.
- Сыркин А.Л. Лечение стабильной стенокардии. Consilium medicum. 2000- 2:470−477.
- Хубеева Д.М., Баталова А. А., Ховаева Я. Б., Берг М. Д. «Ремоделирование сердца, сосудов и микроциркуляции у больных артериальной гипертензии. Влияние триметазидина MB"/ «Пермский медицинский журнал». 2006. — Т.23. — № 4. — С. 56−63.
- Чазов Е.И., Чазова И. Е. Руководство по артериальной гипертонии. М.: Медиа Медика, 2006. С. 201−300.
- Шальнова С.А., Деев А. Д., Карпов Ю. А. от имени участников программы ПРЕМЬЕРА. Артериальная гипертония и ИБС в амбулаторной практике врача кардиолога. Кардиоваскулярная терапия и профилактика 2006−5(2):77−80.
- Шляхто Е.В., Конради А. О. Ремоделирование сердца при гипертонической болезни — патогенетические факторы и прогностическое значение // Науч. Сборник «Кардиология СНГ». — 2003. Т.1. — С.20−25.
- АСС/АНА 2002 Guideline Update for the Management of Patients With Chronic Stable Angina: A Report of the American College of
- Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina). 24−69.
- Algra A, Tijssen J.G., Roelandt J.R., Pool J., Lubsen J. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 1993- 88: 180−85.
- Beere PA, Gragov S, Zarins SK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984- 226:180−200.
- Begona Lopez et al., Effects of Loop Diuretics on Myocardial Fibrosis and Collagen Type I Turnover in Chronic Heart Failure. Journal of the American College of Cardiology Vol. 43, No. 11, 2004, 44−49.
- Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999−33:44−52.
- Ben-Haim SA, Yahalom M, Hayam G et al. Increased variability of repolarization intervals in patients with spontaneous ventricular tachycardia. Ibid, 16,135.
- Berkin K.E., Ball S.G. Essential hypertension: the heart and hypertension // Hypertension. 2001. — Vol. 86. — P. 467−475.
- Biel M., Scheider A., Wahl C. Cardiac NCN channels: structue, function, and modulation // Trends Cardiovasc. Med. 2002. — Vol. 12. — P. 206−213.
- Bigger JT, Fleiss JL, Steinman RC, et al: Frequencydomain measures of heart period variability and mortality after myocardial infarction. Circulation, 1992, 85:164−171.
- Bikkina M, Levy D, EvansJ et al. Left ventricular mass and the risk thestroke in elderly cohort: The Framingham Study. JAMA 1994- 272:33−36.
- Black H., Weltin G., Jaffe C.C. The limited echocardiogram: A modification of standard echocardiography for use in the routine evaluation of patients with systemic hypertension // Amer. J Cardiology. 1991. — Vol. 67. — P. 1027−1030.
- British Hypertension Society guidelines (BHS-IV). J Fam Pract 2004- 53: 528−50.
- Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of Hypertension. Am Heart J 2000- 140 (6): 848−56.
- Bucchi A, Tognati A, Milanesi R et al. Properties of ivabradine-induced block of HCN1 and HCN4 channels. J Physiol 2006- 572 (2): 335−46.
- Camm A.J., Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16 257) in adult patients with normal baseline electrophysiology. Drugs RD 2003- 4:83—89.
- Celermajer D. S. Endothelial dysfunction: does it matter? Is it reversible? J. Am. Coll. Cardiol. 1997- 30:325−333.
- Cerbai E., Barbieri M., Mugelli A. Occurrence and properties of the hyperpolarization-activated current If in ventricular myocytes from normotensive and hypertensive rats during aging // Circulation. 1996. -Vol. 94.-P. 1674−1681.
- Cerbai E., Pino R., Sartiani L., Mugelli A. Influence of postnatal-development of If occurrence and properties in neonatal rat ventricular myocytes // Cardiovasc. Res. 1999. — Vol. 42. — P. 416−423.
- Chaillan F.A. et al. Involvement of tissue inhibition of metalloproteinases-lin learning and memory in mice. Behavioural Brain Research 173 (2006)191.198.
- Chowta K.N., Chowta M. N., Bhat P. et al. An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension // J. Assoc. Physicians India. 2002. — V. 50. — P. 1236−1239.
- Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 2001−345:494−502.
- Colin O., Ghaleh В., Hittinger L. et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise // Amer. J. Physiol. Heart Circ. Physiol. 2002. — Vol. 282. — P. 672−679.
- COMMIT collaborative group. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction randomised placebo-controlled trial. Lancet 2005- 366: 1622−32.
- Crombez L. et al. High level production of secreted proteins: Example of the human tissue inhibitor of metalloproteinases 1. Biochemical and Biophysical Research Communications 337 (2005): 908−915.
- Cruickshank J.M. Reversibility of left ventricular hypertrophy. Blood Press Suppl 1992−1:32−33- discussion 33−34.
- Custodis et al, Circulation 2008- 117: 2377−2387.
- D. Di Francesco. «funny"channels discovery: the first step of a BEAUTIfUL journey. Journal of Clinical Lipidology (2008) 2: 1−3.
- Da browski A, Kramarz E, Kubik L: Prolongation of QT interval correctedfor heart rate by Bazett’s equation and linear formula as predictor of arrhythmic events after myocardial infarction. Am J Cardiol 86:469−472, 2000).
- Dahlof В., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies.// Am J Hypertens. 1992. — № 5. — P.95−110.
- De Simone G., Devereux R.B., Roman M.J. et al. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults // Hypertension. 1994. — Vol. 23. — P. 600−606.
- De Simone G., Pasanisi F., Contaldo F. Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy // Hypertension. — 2001.-Vol. 38.-P. 13−18.
- Demir M. et al. Procollagen type I carboxy-terminal peptide shows left ventricular hypertrophy and diastolic dysfunction in hypertensive patients. Cardiovascular Pathology 16 (2007) 69−74.
- Derad I, Otterbein A, Molle M, Petrowsky R, Born J, Fehm HL. The angiotensin converting enzyme inhibitors fosinopril and enalapril differ in their central nervous effects in humans. J Hypertens 1996- 1309−15.
- Derosa G, D’Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006- 13(3):227−31.
- Devereux R. Therapeutic options in minimizing LVH. Am Heart J 2000- 139: 9−14.
- Devereux R.B. Left ventricular geometry, pathophysiology and prognosis. J Am Coll Cardiol, 1995- 25: 885−887.
- Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparasion to necropsy findings. Am J Cardiol 1986- 57: 450−458.
- Diaz A, Bourassa MG, Guertin MC, et al: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26: 967−974, 2005).
- Diez I., Laviades C, Mayor G. et al. Increased serum concentration of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995,5:1450−1456.
- Forough R., Koyama N., Hasenstab D., Lea H., Clowes M., Nikkari S.T., Clowes A.W. Overexpression of tissue ingibitor of matrix metalloproteinase-1 ingibits vascular smooth muscle cell functions in vitro and vivo. Circ Res. 1996- 79: 812−820.
- Forough R., Lea H., Starcher B. Metalloproteinase Blokade by Local Overexpression of TIMP-1 increases Elastin Accumulation in Rat Carotid Artery Intima. Arteriosclerosis, Trombosis, and Vascular Biology. 1998- 803−807.
- Forough R., Nikkari S.T., Hasenstab D., Lea H., Clowes A.W. Cloning and characterization of a cDNA encoding the ballon tissue ingibitor of matrix metalloproteinase-1 (TIMP-1). Gene. 1995- 163: 267−271.
- Franz H Messerli, Bryan Wiliams, Eberhard Ritz. Essential hypertension, Lancet, 2007- 370: 591−603.
- Fratolla A, Parati G, Cuspidi С et al. Prognostic value of 24-hour blood presser mean and variability. J Hypertens 1993- 11: 1133−1137.
- Gaetano Antonio Lanza The Electrocardiogram as a Prognostic Tool for Predicting Major Cardiac Events. Progress in Cardiovascular Diseases, Vol. 50, No. 2 (September/October), 2007: 87−111.
- Ganau A, DevereuxRB, Roman MJ, de Simone G, Pick ering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. // J Am Coll Cardiol. 1992 Jun. 19(7): 1550−1558.
- Gibbons R.J., Abrams J., Chatterjee K. et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina Summary article // Circulation.- 2003.- № 107.- P. 149−158.
- Gillum R., Makuc D., Feldman J. Pulse rate, coronary heart disease, and death: The NHANES I epidemiologic follow-up study. Am Heart J 1991,121: 172−177.
- Gilman M, Kannel W, Belanger A, D’Agostino R. Influence of heart rate on mortality among persons with hypertension The Framingham study. Am H J 1993- 125: 1148−1154.
- Gomez D.E., Alonso D.F., Yoshiji H., Thorgersson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997- 74:111−122.
- Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290: 891−897.
- Guidelines Subcommittee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003- 21:1011−1053.
- Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task force of the European society of cardiology and the North American society of pacing and electrophysiology// Eur Heart J., 1996, v. 17: 354−381.
- Heusch G., Eur Heart J 2008- 29 (18): 2265−2275.
- Hoppe U.S., Jansen E., Sundkamp M., Beuckelmann D.J. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human heart // Circulation. 1997. — Vol. 97. — P. 55−65.
- Hoppe UC, Jansen E, Sudkampf M et al. A hyperpolarisation-activated inward current (If) in ventricular myocytes from normal and failing human hearts. Circulation 1998- 97: 55−65
- Jackson C. Matrix metalloproteinasas and angiogenesis. Curr. Opin Nephol Hypertens. 2002- 11:3: 295−299.
- James M, Jones J. Ventricular arrhythmia in untreated newly presenting hypertensive patients compared with matched control population. J Hypertens 1989- 7: 409−415.
- JC Tardif, J Camm, JY Le Heuzey Montreal, Quebec, The If current inhibitor ivabradine significantly increases heart rate variability compared with amlodipine in patients with chronic stable angina, Can J Cardiol, 2006, October, Page 686.
- Jean-Claude Tardif, Eur Heart J 2009- Jan 9: 43−50.
- Jeffrey J. Goldberger et al. American Heart Association/American College of
- Joannides R., Moore N., Iacob M., et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 2006- 61:127—137.
- Jondeau G., Korewicki J., Vasitiauskas D. Effects of ivabradine in left ventricular systolic dysfunction and coronary artery disease (Abstract 2637) // Eur. Heart. J. 2004. — Vol. 25 (Suppl.). — P. 491.
- Jouven X, Desnos M, Guerot C, Ducimetiere P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation 1999- 99: 1978−83.
- Jouven X, Empana JP, Schwartz PJ, et al: Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med, 2005, 352:1951−1958.
- Jugdutt B.I., Khan M.I., Jugdutt S.J., et al. Impact of left ventricular unloading after late reperfusion of canine anterior myocardial infarction on remodeling and function using isosorbide-5-mononitrate // Circulationl995- 92: 926−934.
- Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion and complication: effect of timing, dosage and infarct location // Circulation 1988- 78: 906−919.
- Kannel W, Gordon T, Offut D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham Study. Ann Intern Med 1969- 71: 89−105.
- Kannel W.B. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 1991- 9: 3−9.
- Kannel W.B., Gagnon D.R., Cupples L.A. Epidemiology of. sudden coronary death: population at risk. Can J Cardiol 1990- 6: 439−44.
- Kannel WB, Kannel CE, Paffenbarger RS Jr, Cupples LA. Heart rate andcardiovascular mortality in the Framingham study. Am Heart J 1987- 113:1489−1494.
- Kardos А. и соавт. (1998), В- Wennerblom и соавт. (1998) Wennerblom В, Courmel Ph, Hermida JS, et al. Heart rate variability in myocardial hypertrophy and heart failure, and effects of beta-blocking therapy. Eur Heart J 1991−12:412−422.
- Katz R.J., Levy W.S., Buff L., et al. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors // Circulation 1991−83:1271−1277.
- Khattar R. Longitudinal association of ambulatory pulse pressure with left ventricular mass and vascular hypertrophy in essential hypertension/ R. Khattar, D. Acharya, N. Kinsey// J. Hypertens. 1997. — № 15. — P. 737−743.
- Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003- 290: 898−904.
- Kleiger RE, Miller JP, Bigger JT, et al: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol, 1987, 59: 256−262.
- Klingbeil A.U., Schneider M., Martus P. et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003−115:41−46.
- Koren M, Richard B, Devereux M et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hipertension. Ann Intern Med 1991- 114: 345−52.
- Koren M, Ulin R, Laraghf Devereux R. Changes in LVH predict risk in essential hypertension. Cerculation.1990- 83: 111−129.
- Lanza GA, Cianflone D, Rebuzzi AG, et al: Prognostic value of ventricular arrhythmias and heart rate variability in patients with unstable angina. Heart, 2006, 92:1055−1063.
- Laurent GJ. Dynamic state of collagen: pathwayas of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol. 1987- 252: 1−9.
- Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998- 6: 53540.
- Levy D, Anderson KM, Savage DD et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol, 7: 285−292.
- Levy D, Garrison R, Savage D et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990- 322: 1561−6.
- Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988- 56 (Suppl. 5): 1−5.
- Levy D., Svage D., Garrison R. et al. Echocardiographic criteria for left ventricular hypertrophy (The Framingham Heart Study) // Amer. J. Cardiology. 1987. — Vol. 59. — P. 956−960.
- Liao Y, Cooper R, Mensah G et al. The relative effects of left ventricularhypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995- 273: 1592−7.
- Lindsay, M.M. et al. (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40, 136—141.
- Lindsey Merry L., Spinale Francis G., Targeting matrix remodeling in cardiac hypertrophy and heart failure. Drug Discovery Today: Therapeutic Strategies Vol. 2, No. 3 2005: 67−70.
- Lonardo C., Stillitano F., Zicha S. et al. Molecular basis of funny current If in normal and failing human heart // Circulation. 2004. — Vol. 110 (Suppl. III).-P. 129.
- Lorenzo Lopez-Bescos, Slavomira Filipova, Ramon Martos, on behalf of the studyinvestigators. Long-Term Safety and Efficacy of Ivabradine in Patients with Chronic Stable Angina. Cardiology 2007- 108: 387−396.
- Manuel F. Jimenez-Navarro et al., Collagen Synthesis and Heart Failure. Rev Esp Cardiol. 2005- 58(8): 975−978.
- Manz M., Reuter M., Lauck G., et al. A single intravenous dose of ivabradine, a novel 1(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 2003- 100:149−155.
- Mauss O, Klingenheben T, Ptaszynski P, et al: Bedside risk stratification after acute myocardial infarction: prospective evaluation of the use of heartrate and left ventricular function. J Electrocardiol, 2005, 38:106−112.
- Messerly FN, Grodzicki T. Hypertensive left ventricular hypertrophy, ventricular arrhythmias and sudden death. Eur Heart J 1992- 13 (Suppl. D): 66−69.
- Mukaddam-Daher S., Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides.// Braz J Med Biol Res. 2004. — Vol. 37. — № 8. -P.1239−1245.
- Myerburg R.J., Kessler K.M., Estes D. et al. Long-term survival after prehospital cardiac arrest: Analysis of outcome during an 8 year study //Circulation. 1984. — Vol. 70. — P. 538−546.
- Nadir Ulu et al, J Cardiovascular Pharmacol 2009- 51(1): 9−17.
- Nagase H. Activation mechanisms of matrix metalloprotemases. Biol Chem 1997- 378: 151−160.
- Nunez BD, Lavie CJ. Comparison of diastolic left ventricular filling and cardiac dysrhythmias in hypertensive patients with and without isolated septal hypertrophy. Am J Cardiol 1994- 74: 585−590.
- Nyman I, Areskog M, Areskog NH, et al: Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group. J Intern Med, 1993, 234: 293−301.
- O’Rourke M.F. Оптимизация отражения волны: терапия будущего? Сердечно-сосудистое ремоделирование. 1998. С. 37−41.
- Papandonakis Е, Tsoukas A, Christakos S: QT dispersion as a noninvasivearrhythmogenic marker in acute myocardial infarction. Ann Noninvasive Electrocardiol, 1999, 4: 35−38.
- Paul Milliez, Am J Physiol Heart Circ Physiol 2009- 296: 435−441.
- Paul Milliez. Am J Physiol Heart Circ Physiol, 2009, 296: 435−441.
- Podrid P.J. Management of arrhythmias in heart failure and cardiomyopathy // Heart Failure / Ed. D.L. Mann. Philadelphia: Saunders, 2004. — P. 683 704.
- Pohjola-Sintonen S, Siltanen P, Haapakoski J: Usefulness of QTc interval on the discharge electrocardiogram for predicting survival after acute myocardial infarction. Am J Cardiol, 1986, 57: 1066−1068.
- Puljevic D., Smalcelj A., Durakovic Z. et al. Effects of postmyocardial infarction scar size, cardiac function, and severity of coronary artery disease on QT interval dispersion as a risk factor for complex ventricular arrhythmia
- РАСЕ. 1998. — Vol. 21. — P. 1508−1516.
- Raffetto Joseph D., Khalil Raouf A., Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochemical pharmacology 75 (2008): 346−359.
- Rajagopalan S., Pitt B. Aldosterone as a target in congestive heart failure. Med. Clin. North. Am. 2003 Mar- 1987(2): 441−457.
- Robert Lux, Paulus Kirchhof, Iwona Cygankiewcz, Konrad Brockmeier. Electrocardiographic markers of sudden cardiac death. Journal of Electrocardiology, 40 (2007): 9−10.
- Romero, J.R., et al., Association of matrix metalloproteinases with MRI indices of brain ischemia and aging. Neurobiol. Aging (2009), 5: 78−80.
- Sana M. Al-Khatib et al. Preventing tomorrow’s sudden cardiac death today: Part I: Current data on risk stratification for sudden cardiac death. Am Heart J 2007- 153:941−50.
- Sartiani L., Cerbai E., De Paoli P. et al. The expression and pharmacological modulation of the pacemaker current in ventricular myocytes from postmyocardiol infarction // Circulation. 2000. — Vol. 102. — P. 129.
- Schmieder RE, Schlaich MP, Klingbeli AU et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomaized double-blind studies until December 1996). Nephrol Dial Transplant 1998- 13: 554−69.
- Seccareccia F, Pannozzo F, Dima F, et al: Heart rate as a predictor of mortality: the MATISS project. Am J Public Health, 2001, 91: 1258−1263.
- Senior R.M., Griffin G.L., Fliszar C.J., Shapiro S.D., Goldberg G.I., Welgus H.G. Human 92- and 72-kilodaltontype 4-kollagenases are elastases. J Biol Chem. 1991- 266: 7870−7875.
- Shusterman V., Beigel A., Shah S.I. et al. Changes in autonomic activity and ventricular repolarization. // J Electrocardiol 1999- 32:185−92.
- Simon L., Chalen В., Puybasset L. et al. Coronary and hemodynamic effects of SI6257, a new bradycardic agent, in resting and exercising conscious dogs // J. Pharmacol. Exp. Ther. 1995. — Vol. 275. — P. 659−666.
- Simone G, Mureddu G, Greco R et al. Relation of left ventricular geometry and function to body composition in children with high causal blood pressure. Hypertension 1997- 30: 377—382.
- Singer D.H., Ori Z. Changes in heart rate variability associated with sudden cardiac death. In: Malik M., Camm A.J., eds. Heart rate variability. Armonk: Futura. -1995.-P.429−448.
- Singh B.N. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate // J. Cardiovasc Pharmacol Therapeut. 2001. — Vol. 6. -P. 313−331.
- Spargias KS, Lindsay SJ, Kawar GI, et al: QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. Eur Heart J, 1999, 20: 1158−1165.
- Steen D. Kristensen et al. Highlights of ESC 2008 Scientific Sessions // Journal of the American College of Cardiology. Vol. 52, No. 24, December 9, 2008: 2032−2042.
- Stilli D., Sgifo A., Macchi E. et al. Myocardial remodeling and arrhythmogenesis in moderate cardiac hypertrophy in rats // Amer. J. Physol. -2001.-Vol. 280.-P. 142−150.
- Sumeet S. Chugh, et al. Epidemiology of Sudden Cardiac Death: Clinical and Research Implications. Progress in Cardiovascular Diseases, Vol. 51, No. 3 (November/December), 2008: 213−228.
- Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology: Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation, 1996, 93:1043−1065.
- Tavazzi L., Mugelli A. Can If inhibition help in congestive heart failure? // Dial. Cardiovasc. Med. 2006. — Vol. 11. — P. 30−35.
- Tayebjee, M.H. et al. (2005) Tissue inhibitor of metalloproteinse-1 is a marker of diastolic dysfunction using tissue Doppler in patients with type 2 diabetes and hypertension. Eur. J. Clin. Invest. 35, 8—12.
- The REACH registry Investigators. JAMA. 2006, 295: 180−189.
- Toutouras P., Vlachopoulos C., Pressure diameter relationship of thehuman aorta: a new method of determination by the application of a specialultrasonic dimension catheter. Circulation. 1995. 92: P. 2210−2219.
- Vakili B, Okin P, Devereux R. Prognostic implications of left ventricular hypertrophy. AmHeartJ2001- 141: 334−341.
- Vilaine J.P., Bidouard J.P., Lesage L. et al. Anti-ischemic effects of ivabradin, a selective heart-rate reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovascular Pharmacol 2003- 42: 688−696.
- Vita J.A., Treasure C.B., Nabel E.G. et al. Coronary vasomotor responses to acetylcholine relate to risk factors for coronary artery disease. Circulation 1990−81:491−497.
- Wannamethee G., Shaper A.G., Macfarlane P.W., Walker M. Risk factors for sudden cardiac death in middle-aged Britishmen. Circulation 1995- 91: 1749−1756.
- Weber KT, Sun Y, Dhalla AK, R.V. G. Extracellular matrix and fibrosis in cardiac hypertrophy. In Sheridan DJ (ed) Left Ventricular Hypertrophy, Edition 1. London, UK: Churchill Ltd 1998- 6: 37−44.
- Wennerblom В., Lurje L., Karlsson Т., et al. Circadian variation of heart rate variability and the rate of autonomic change in the morning hours in healthy subjects and angina patients // Int J Cardiol 2001- 79(1): 61−69.
- Woessner, J.F., Jr (2002) MMPs and TIMPs an historical perspective. Mol. Biotechnol. 22, 33−49.
- Yamamoto, K. et al. (2002) Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensiveheart. Cardiovasc. Res. 2003, 55: 76−82. J
- Yu H., Chang F., Cochen I.S. Pacemaker current exists in ventricular myocytes // Circul. Res. 1993. — Vol. 72. — P. 232−236.
- Zaputovic L, Mavric Z, Zaninovic-Jmjevic T, et al: Relationship between QT dispersion and the incidenc of early ventricular arrhythmias in patients with acute myocardial infarction. Int J Cardiol, 1997, 62: 211−216.
- Zareba W, Moss AJ, Le Cessie S: Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol, 1994, 74: 550−553.